



Curetis AG Appoints Dr. Klaus Brinkmann as Director of Sales

Preparation of CE-marking and product launch in Europe in 2012

Holzgerlingen, Germany, December 13, 2011 -- Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced that Dr. Klaus Brinkmann has joined its management team as Director of Sales.

Dr. Klaus Brinkmann is a seasoned executive with extensive commercial expertise in setting-up sales organizations and infrastructures and leading sales teams in very competitive markets. He has an outstanding track record in the commercialization of complex in vitro diagnostics (IVD). His experience covers instrument platforms as well as test kits in the areas of immunology, traditional microbiology and molecular-based infectious disease testing. He joins Curetis from BioRad Laboratories GmbH, where he has been Account Manager Lab Automation. Previously, he held various sales management positions with Becton Dickinson GmbH and Beckman Coulter GmbH. Klaus Brinkmann studied chemistry and holds a doctorate from Justus Liebig University Giessen, Germany.

“We are very pleased that Klaus has joined our team”, said Oliver Schacht, CEO of Curetis. “He brings 15 years of IVD sales experience in the hospital market and a strong customer network, which is exactly what we need for the commercial launch of our Unyvero™ System next year. Klaus will guide the setting-up of our commercial infrastructure. He will lead our sales team for the DACH markets and will also initiate the build-up of an international distributor network in other European countries and selected global markets.”

The Unyvero™ System developed by Curetis for the first time allows for the fully automated, unsupervised performance of highly complex assays to identify pathogens and antibiotic resistances in less than 4 hours. With the Unyvero™ System, the company is addressing a €1.6 billion, growing market for molecular diagnostics of severe infections in the EU and the US. The first Unyvero™ cartridge, Unyvero™ P50, is targeting the pneumonia testing market which today consists of 22.6 million tests p.a. in Europe and the US. Commercial launch of the platform and the P50 cartridge in Europe is expected for the first half of 2012.

###

About the Unyvero™ System

The Unyvero™ System is a versatile hardware platform for the detection of a broad panel of bacteria and antibiotic resistances from a single sample in one run. It processes a disposable cartridge providing the necessary reagents to complete the analysis from sample to result.

The platform enables the DNA-based testing of all clinically relevant samples in a fully automated, unsupervised analysis process requiring only few, quick manual preparation steps. The analysis thus can be performed with minimal operator time and without the need of skilled staff or special infrastructure.

Thereby, clinically relevant information is available within less than four hours to support an informed therapy decision as early as possible.

The first Unyvero™ Cartridge, Unyvero™ P50, focuses on pneumonia testing and simultaneously analyses 39 DNA targets. Cartridges for further applications, e.g. for surgical site infections, blood stream infections and tuberculosis, are in preparation.

About Curetis (Germany)

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis AG will enable rapid multiparameter pathogen and antibiotic resistance detection in only a few hours, a process that today can take up to days or even weeks with other techniques.

To date, Curetis has raised total funds of over € 36.6 million (~ USD 50 million). The company is based in Holzgerlingen near Stuttgart, Germany. In 2011, Curetis signed a collaboration agreement with Sanofi Pasteur for the potential use of the Unyvero™ platform in a future global clinical trial.

Contact

Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany

Tel. +49 (0) 7031 49195-10

pr@curetis.com
www.curetis.com

Media Inquiries:

akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partner

info@akampion.com
Tel. +49 40 88 16 59 64

Press Release Curetis AG

Tel. +49 30 23 63 27 68